New Trial Suggests CV Benefit With EPA: RESPECT-EPA

A new Japanese study of highly purified eicosapentaenoic acid (EPA; icosapent ethyl) has suggested a possible benefit in reducing adverse cardiovascular events in patients with chronic coronary artery disease taking statins.

The open-label randomized RESPECT-EPA study showed a reduction of borderline statistical significance in its primary endpoint of a composite of cardiovascular death, nonfatal myocardial infarction (MI), nonfatal ischemic stroke, unstable angina, and coronary revascularization  in patients allocated to the EPA product at a dosage of 1800 mg/day.

Source: MEDspace